💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Ibutilide

CHEMBL533 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
384.6 g/mol
LogP
4.0
Phase
4

This antiarrhythmic drug is used to rapidly convert atrial fibrillation or atrial flutter to normal sinus rhythm. It works primarily by prolonging cardiac action potentials through effects on potassium and sodium ion channels. It is given by intravenous infusion in a monitored setting due to the risk of potentially life-threatening ventricular arrhythmias.

Молекулярная масса

384,6000 g/mol

LogP

4,00

TPSA

78,00 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Atrial Fibrillation

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1

                

                

                
                

                    
InChI

                    
InChI=1S/C20H36N2O3S/c1-4-6-7-8-9-16-22(5-2)17-10-11-20(23)18-12-14-19(15-13-18)21-26(3,24)25/h12-15,20-21,23H,4-11,16-17H2,1-3H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C20H36N2O3S

                    

                    
                    

                        
HBD / HBA

                        
2 / 5

                    

                    
                    

                        
Вращаемые Связи

                        
14

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
26

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
This antiarrhythmic drug is used to rapidly convert atrial fibrillation or atrial flutter to normal sinus rhythm. It works primarily by prolonging cardiac action potentials through effects on potassium and sodium ion channels. It is given by intravenous infusion in a monitored setting due to the risk of potentially life-threatening ventricular arrhythmias.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Ibutilide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL533.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 60753.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.